Package Leaflet: Information for the Patient
Everolimus Ethypharm 2.5 mgEFG tablets
Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
Contents of the pack
Everolimus Ethypharm is a cancer medicine that contains the active substance everolimus. Everolimus reduces the blood supply to the tumor and delays the growth and spread of cancer cells.
Everolimus Ethypharm is used to treat adult patients with:
Everolimus Ethypharm will only be prescribed for you by a doctor with experience in the treatment of cancer. Follow your doctor's instructions carefully. They may be different from the general information contained in this leaflet. If you have any questions about Everolimus Ethypharm or why you have been prescribed this medicine, ask your doctor.
Do not takeEverolimus Ethypharm
If you think you may be allergic, consult your doctor.
Warnings and precautions
Talk to your doctor before startingEverolimus Ethypharmif:
Everolimus may also:
Tell your doctor if you are scheduled to receive radiation therapy soon, or if you have received radiation therapy in the past.
Tell your doctorif you experience these symptoms.
During treatment, you will have regular blood tests. These tests will determine the number of cells in the blood (white blood cells, red blood cells, and platelets) to check if everolimus is having an unwanted effect on these cells. You will also have blood tests to monitor kidney function (creatinine level), liver function (transaminase level), and blood sugar and cholesterol levels. These tests are done because they may be affected by treatment with everolimus.
Children and adolescents
Everolimus Ethypharm should not be given to children or adolescents (under 18 years).
Other medicines andEverolimus Ethypharm
Everolimus Ethypharm may affect how other medicines work. If you are taking other medicines at the same time as Everolimus Ethypharm, your doctor may change the dose of Everolimus Ethypharm or the other medicines.
Tell your doctor or pharmacist if you are using, have recently used, or might use any other medicines.
The following may increase the risk of side effects with everolimus:
used to treat bacterial infections.
used to inhibit the growth of abnormal cells.
The following may reduce the effectiveness of everolimus:
These medicines should be avoided during treatment with everolimus. If you are taking any of them, your doctor may prescribe a different medicine or change your dose of everolimus.
TakingEverolimus Ethypharmwith food and drink
Do not take grapefruit or grapefruit juice while taking Everolimus Ethypharm. It may increase the amount of Everolimus Ethypharm in the blood, possibly to a harmful level.
Pregnancy, breastfeeding, and fertility
Pregnancy
Everolimus may harm the fetus and should not be used during pregnancy. Tell your doctor if you are pregnant or think you may be pregnant. Your doctor will discuss with you whether you should take this medicine during pregnancy.
Women who may become pregnant should use a highly effective method of contraception during treatment and for up to 8 weeks after finishing treatment. If, despite these measures, you think you may be pregnant, consult your doctor beforetaking this medicine again.
Breastfeeding
Everolimus may harm the breastfed baby. You should not breastfeed while taking Everolimus Ethypharm and for 2 weeks after the last dose of everolimus. Tell your doctor if you are breastfeeding.
Female fertility
In some patients treated with everolimus, absence of menstrual periods (amenorrhea) has been observed.
Everolimus may have an impact on female fertility. Tell your doctor if you want to have children.
Male fertility
Everolimus may affect male fertility. Consult your doctor if you want to father a child.
Driving and using machines
If you feel abnormally tired (fatigue is a very common side effect), be careful when driving or using machines.
Everolimus Ethypharm contains lactose
This medicine contains lactose (milk sugar). If your doctor has told you that you have an intolerance to some sugars, consult your doctor before taking this medicine.
Follow the instructions for administration of this medicine exactly as told by your doctor or pharmacist. If you are unsure, consult your doctor or pharmacist again.
The recommended dose is 10 mg, once a day. Your doctor will tell you how many Everolimus Ethypharm tablets to take.
If you have liver problems, your doctor may start treatment with a lower dose of Everolimus Ethypharm (2.5; 5; or 7.5 mg per day).
If you experience side effects while taking Everolimus Ethypharm (see section 4), your doctor may reduce the dose you take or interrupt treatment for a short period or permanently.
Take Everolimus Ethypharm once a day, at about the same time, always with food or always without food.
Swallow the tablet(s) whole with a glass of water. The tablets should not be chewed or crushed.
If you take moreEverolimus Ethypharmthan you should
In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicology Information Service (Tel. 91 562 04 20) indicating the medicine and the amount taken.
If you forget to takeEverolimus Ethypharm
If you miss a dose, take the next dose at the scheduled time. Do not take a double dose to make up for missed doses.
If you stop takingEverolimus Ethypharm
Do not stop taking Everolimus Ethypharm unless your doctor tells you to.
If you have any further questions about the use of this medicine, ask your doctor or pharmacist.
Like all medicines, this medicine can cause adverse effects, although not all people suffer from them.
DISCONTINUE treatment with everolimus and seek immediate medical attention if you experience any of the following signs of an allergic reaction:
The serious adverse effects of everolimus include:
Very Common(may affect more than 1 in 10 people)
Common(may affect up to 1 in 10 people)
Uncommon(may affect up to 1 in 100 people)
Rare(may affect up to 1 in 1,000 people)
If you experience any of these adverse effects, inform your doctor immediately as they could have fatal consequences.
Other possible adverse effects of everolimus include:
Very Common(may affect more than 1 in 10 people)
Common(may affect up to 1 in 10 people)
Uncommon(may affect up to 1 in 100 people)
Rare(may affect up to 1 in 1,000 people)
Frequency Not Known(cannot be estimated from the available data)
If these adverse reactions worsen, inform your doctor and/or pharmacist. Most adverse effects are mild to moderate and usually disappear if treatment is discontinued for a few days.
Reporting of Adverse Effects
If you experience any type of adverse effect, consult your doctor or pharmacist, even if it is a possible adverse effect that is not listed in this leaflet. You can also report them directly through the Spanish Pharmacovigilance System for Human Use Medicines: www.notificaRAM.es. By reporting adverse effects, you can contribute to providing more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiration date stated on the packaging and blister. The expiration date is the last day of the month indicated.
Do not store above 25°C.
Store in the original packaging to protect from light.
Open the blister just before taking the tablets.
Do not use this medicine if you notice that the packaging is damaged or shows signs of tampering.
Medicines should not be disposed of via wastewater or household waste. Deposit the packaging and medicines you no longer need at the SIGRE collection point in your pharmacy. If in doubt, ask your pharmacist how to dispose of the packaging and medicines you no longer need. This will help protect the environment.
Composition of Everolimus Ethypharm
Each Everolimus Ethypharm tablet contains 2.5 mg of everolimus.
Appearance of the Product and Package Contents
The Everolimus Ethypharm 2.5 mg tablets are white to off-white, oblong tablets, 9.6 x 4.5 mm. They are marked with "E" on one side and "2.5" on the other.
Everolimus Ethypharm 2.5 mg is available in packages containing 30 or 90 tablets.
Not all pack sizes may be marketed.
Marketing Authorization Holder
Ethypharm
194 Bureaux de la Colline – Bâtiment D
92213 Saint-Cloud cedex
France
Manufacturer
Ethypharm
Chemin de la Poudrière
76120 Grand Quevilly
France
Ethypharm
Z.I. de Saint Arnoult
28170 Châteauneuf en Thymerais
France
You can request more information about this medicine by contacting the local representative of the marketing authorization holder:
ALTAN PHARMACEUTICALS S.A.
C/Colquide, Nº 6, Portal 2, 1ª planta, Oficina F. Edificio Prisma
Las Rozas (Madrid)
28230 Spain
This medicine is authorized in the Member States of the European Economic Area under the following names:
Sweden: | Everolimus Ethypharm 2.5 mg, tablets |
Austria: Germany: | Everolimus Ethypharm 2.5 mg, tablets Everolimus Ethypharm 2.5 mg, tablets |
Denmark: Italy: | Everolimus Ethypharm 2.5 mg, tablets Everolimus Ethypharm |
Finland: Netherlands: Norway: Portugal: | Everolimus Ethypharm 2.5 mg, tablets Everolimus Ethypharm 2.5 mg, tablets Everolimus Ethypharm Everolimus Ethypharm 2.5 mg, tablets |
Spain: | Everolimus Ethypharm 2.5 mg, tablets EFG |
United Kingdom: | Everolimus Ethypharm 2.5 mg, tablets |
Date of the last revision of this leaflet 04/2023.
Detailed information about this medicine is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) http://www.aemps.gob.es/.
The best alternatives with the same active ingredient and therapeutic effect.
Discuss dosage, side effects, interactions, contraindications, and prescription renewal for EVEROLIMUS ETHYPHARM 2.5 mg TABLETS – subject to medical assessment and local rules.